J.P. Morgan analyst Richard Vosser maintained a Sell rating on Roche Holding AG (RHHVF – Research Report) today and set a price target of CHF210.00. The company’s shares closed yesterday at $259.80.
According to TipRanks, Vosser is a 5-star analyst with an average return of 8.2% and a 57.80% success rate. Vosser covers the Healthcare sector, focusing on stocks such as Roche Holding AG, Sanofi, and Bayer.
The word on The Street in general, suggests a Hold analyst consensus rating for Roche Holding AG with a $299.37 average price target, representing a 15.23% upside. In a report released on February 16, Morgan Stanley also maintained a Sell rating on the stock with a CHF250.00 price target.
See today’s best-performing stocks on TipRanks >>
RHHVF market cap is currently $209B and has a P/E ratio of 15.93.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Roche Holding AG (RHHVF) Company Description:
Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.
Read More on RHHVF:
- Roche price target lowered to CHF 250 from CHF 260 at Morgan Stanley
- FDA approves Xolair as first and only medicine for children and adults with one or more food allergies
- Genentech’s Xolair approved by FDA for children, adults with food allergies
- Roche enters collaboration agreement with PathAI to develop pathology algorithms
- Repare Therapeutics to regain global rights to Camonsertib
